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Abstract
The NIH, FDA and CDC offer a wide spectrum of job opportunities focused on improving public 
health through the discovery and translation of research, the regulation of safe and effective 
medicines, and the protection of health security.
As immunologists approach the end of their training, many face the question of their next 
career step. Many researchers seek careers inside academia, the pharmaceutical and 
biotechnology industry and others. An attractive alternative is pursuing a scientific career in 
government institutions. Careers with government agencies are highly regarded and offer an 
interesting array of stable job opportunities for immunologists in which their work can have 
an effect on a diverse range of public health issues. This Commentary focuses particularly 
on three institutions with a long history of discovery, innovation, safeguarding and 
advancing public health: The US National Institutes of Health (NIH), the US Food and Drug 
Administration (FDA) and the Centers for Disease Control and Prevention (CDC).
The NIH
The NIH is the world’s largest biomedical research institution and funding agency (http://
www.nih.gov/about/). It is composed of 27 institutes and centers with scientific agendas 
focused on specific diseases and/or biological systems in which immunologists can pursue 
scientific careers. The vast majority of the NIH’s budget (~90%) goes to the extramural 
research community and funds researchers in academic and private institutions located in the 
United States and around the world through competitive grants1,2. The remaining 10% of the 
NIH’s budget supports the research of its intramural laboratories at several locations in the 
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USA. In a global world with diseases such as tuberculosis, malaria, HIV-AIDS and other 
emerging infectious diseases, cancer, autoimmunity, allergy and rare undiagnosed diseases, 
these institutes and centers house a continuum of biomedical research, ranging from the 
most basic research to translational research for the treatment and prevention of these 
diseases3–5.
The NIH has a long tradition in immunology and infectious diseases dating from 1887 with 
the creation of the Laboratory of Hygiene at Staten Island. Driven by the growing need for 
research, immunology at the NIH has only grown. Some aspects of immunology research at 
the NIH in the early 1960s are reflected in a fascinating chapter by William E. Paul and 
Thomas A Waldmann in NIH: An Account of Research in its Laboratories and Clinics6. 
Today, at the main campus in Bethesda, Maryland, and its other locations in the country, the 
NIH Intramural Research Program hosts one of the largest and most productive immunology 
communities in the world, with over 200 laboratories distributed in its various institutes and 
centers7 (http://irp.nih.gov/our-research/scientific-focus-areas/immunology). Among the 
many seminal discoveries of NIH immunologists are the cloning of T cell antigen receptor 
β-chain; the discovery of interleukin 2 (IL-2), IL-3, IL-4 and IL-15, as well as of chains of 
the IL-2 receptor; the elucidation of the three-dimensional structure of antibodies; and the 
co-discovery of the causative agent of HIV-AIDS. This extraordinary assemblage of 
researchers and clinicians, including world leaders in the immunology field, nurture the 
development of new generations of immunologists with a PhD and/or MD at the NIH’s 
state-of-the-art laboratories and Clinical Center facilities. Immunologists across the NIH 
share membership in the Immunology Interest Group, which currently has over 500 
members. This group promotes interactions inside and outside the community through 
scientific activities such as its weekly Lectures Series. Another important activity is its 
yearly workshop, a two-day symposium that gathers the NIH’s immunologists, largely from 
the intramural program. At this workshop this community can be seen in action, with senior 
investigators providing one-on-one feedback to trainees presenting their research work and 
engaged in exciting discussions, all on one central topic: immunology. The NIH intramural 
immunology community also has cross-fertilizing groups, such as the NCI Center of 
Excellence in Immunology, the trans-NIH Center for Human Immunology and the 
Translational Immunology Section at National Institute of Arthritis and Musculoskeletal and 
Skin Diseases.
The stable funding provided by the Intramural Research Program of the NIH allows 
scientists from basic and clinical research to enjoy the freedom to pursue new interests and 
engage in innovative high-risk, high-reward research projects. For those interested in 
following a bench-scientist career as a Tenure-Track/Tenure Eligible Investigator, the NIH 
offers excellent opportunities for outstanding young researchers, such as the trans-NIH 
Stadtman Tenure-Track Investigator position for laboratory-based researchers, as well as the 
Lasker Clinical Research Scholars Program for clinical investigators. The NIH also issues 
early Independent Scientist Awards to support particularly talented recent doctoral graduates 
in independent positions without the requirement of post-doctoral training. The available 
resources and the remarkable and diverse research environment also attract Senior 
Investigator–level recruits oriented to foster or initiate new specific programs, both basic and 
clinical.
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At the laboratories of the Intramural Research Program, Staff Scientist (for those with a 
PhD) and Staff Clinician (for those with an MD) are positions for outstanding researchers 
who work in close partnership with the Senior Investigators and Tenure-Track/Tenure 
Eligible Investigators who support their research programs. These are long-term positions 
and can have a wide range of functions, responsibilities and independence, from working at 
the bench to leading basic and clinical research teams, developing new research programs 
and managing core facilities. In some cases, a position as a Staff Scientist or Staff Clinician 
can evolve into a tenure-track investigatorship. In this setting, basic scientists work in close 
proximity to clinical immunologists (physicians, dentists and doctoral-level researchers) at 
the NIH Clinical Center, the largest clinical research hospital in the US. To quote Alan Sher 
(Chief of Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious 
Diseases):
“…the close and highly enthusiastic interaction of basic scientists and clinical 
researchers makes the NIH a unique place to work on human disease. It is an 
environment where, both bedside-to-bench and bench-to-bedside research programs 
are strongly encouraged.”
At the NIH Clinical Center, multidisciplinary teams of researchers formed by basic and 
clinical immunologists and other specialties work together with the ultimate goal of 
understanding human diseases, developing new treatments and translating discoveries from 
intramural laboratories into clinical protocols to determine their effect on human disease. In 
addition to the translation into clinic of vaccines and immunotherapies for cancer, 
autoimmunity and infectious diseases, among others, the NIH supports research programs to 
fill gaps in knowledge and help in promoting the rapid translation of new treatment options 
for those patients suffering from rare and undiagnosed diseases. The dynamic partnerships 
between basic researchers and clinical researchers working together to understand human 
diseases is an distinctive feature of the working experience at the NIH, and its essence is 
captured by H. Clifford Lane (Director of the Division of Clinical Research, National 
Institute of Allergy and Infectious Diseases), who mentioned that
“…over the years the NIH-Clinical Center provided a place for rapid translation of 
bench research to clinical investigation. It is also noteworthy for its ability to 
rapidly adapt to new challenges such as HIV-AIDS, SARS and most recently 
Ebola.”
The Intramural Research Program of the NIH fosters international research programs around 
the world in disease-endemic countries to address critical global health issues. By promoting 
sustainable partnerships and building infrastructure and scientific capacity, these initiatives 
encourage the exchange of scientific knowledge between researchers and provide training 
opportunities to strength biomedical research capacity in the host countries. Basic and 
clinical immunologists at the NIH working in multicultural environments can make 
important contributions in addressing global heath challenges. In addition to the research 
career opportunities, these programs provide a career track for those immunologists 
interested in global health science and policy.
The NIH plays a critical role in the scientific community by funding immunology research 
in the United States and around the world. Each institute has an extramural program 
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consisting of immunologists with an MD and/or PhD who serve as Scientific Review 
Officers and Program Directors. These programs offer another remarkable career 
opportunity for outstanding and experienced immunologists interested in developing careers 
in these areas. These positions require sophisticated knowledge of research and continuous 
understanding of advances in the field of immunology. Ricardo Cibotti (Program Director, 
National Institute of Arthritis and Musculoskeletal and Skin Diseases) said that
“some of the most rewarding aspects of a NIH Extramural Program Director’s job 
include interacting with new investigators who are planning research project 
submissions to NIH, promoting and advocating the best science, and helping to 
generate promising initiatives that will accelerate discovery and development of 
basic and clinical research.”
Overall, there are many exciting career opportunities in biomedical research, medicine, 
science policy, regulatory affairs and other areas that the NIH has to offer. Given this, the 
NIH is a unique and attractive institution for young scientists establishing their careers in 
immunology.
The FDA
The FDA provides a diverse array of opportunities for outstanding well-trained scientists 
who want to have a clear and direct effect on public health. As with research at the NIH, 
scientists can pursue careers at the bench or away from it, but at the FDA, science is 
obviously focused on its mission (http://www.fda.gov/aboutfda/whatwedo/):
“FDA is responsible for protecting the public health by assuring the safety, efficacy 
and security of human and veterinary drugs, biological products, medical devices, 
our nation’s food supply, cosmetics, and products that emit radiation.
FDA is also responsible for advancing the public health by helping to speed 
innovations that make medicines more effective, safer, and more affordable and by 
helping the public get the accurate, science-based information they need to use 
medicines and foods to maintain and improve their health….”
The opportunity to work in a public health environment and make a difference to patients 
and society is what most scientists highlight when discussing their experience. In the words 
of Sue Epstein (Associate Director for Research, Center for Biologics Evaluation and 
Research),
“I had come of age during the heyday of the civil rights movement, including five 
years living on the South Side of Chicago. I wanted to work in a socially relevant 
field, one that could benefit people of all walks of life…. Here, I can lead an 
immunology research program, review product applications and participate in a 
license review and inspection, develop regulatory policy at the dawn of the fields of 
gene therapy and cell therapy, and participate in WHO meetings on influenza 
control.”
Immunologists who choose to leave active bench science and take positions reviewing 
product chemistry and manufacturing can expect to be part of multidisciplinary teams that 
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include clinicians, chemists, microbiologists, toxicologists, clinical pharmacologists and 
chemical engineers. These teams work together to regulate the various aspects of a product, 
starting before the first studies in humans that test clinical safety through to the licensing 
process and post-marketing stage. There are also opportunities to focus on surveillance 
systems to detect post-marketing safety lapses, as well as on manufacturing compliance 
issues, both of which require the application of scientific knowledge to tie product quality 
issues to product safety and efficacy or to pursue issues of policy.
For those who want to further their careers as researchers, an important feature that 
distinguishes the FDA is that scientists conduct research in parallel with their regulatory 
review duties or are in direct contact with teams of reviewers for products under clinical 
development. Thus, they are uniquely positioned to understand the challenges that limit the 
clinical development or regulation of therapeutic products. Accordingly, research projects 
are geared toward the acquisition of critical knowledge in areas that facilitate the 
development of novel regulatory paradigms and provide scientific support for the 
development and application of new regulatory policy and decision-making. While 
undertaking a dual role as a researcher-reviewer can be challenging, the hands-on expertise 
in bioanalytical methods in silico and in vitro, as well as in animal models that can be used 
to improve product characterization, provides reviewers with knowledge to understand the 
products they regulate. Conversely, the first-hand experience with regulatory submissions 
allows researchers to formulate questions that address scientific gaps that needed to be filled 
to support regulatory decision-making.
With labs located in brand new state-of-the-art laboratory complexes furnished with key core 
facilities, the FDA’s immunologists perform cutting-edge studies in almost every field of 
immunology, including adjuvants and immunomodulators, immunotolerance, stem cell 
biology, inflammation, cancer therapeutics, autoimmunity and infectious diseases, as well as 
a strong program in vaccine development. For example, the innate immunity laboratory uses 
a variety of in vitro and in vivo models to study the immunomodulatory effects of agonists 
of the innate immune system in various tissues. This informs not only the evaluation of new 
vaccine adjuvants and cancer therapies for which molecules are being developed to trigger 
and shape the desired immune response but also the fields of therapeutic proteins and 
‘biosimilars’ for which immune responses can have dramatic consequences. Indeed, 
improved understanding of the immunomodulatory effects of innate immunomodulating 
impurities is helping industry improve the quality of its products and has allowed the FDA to 
make critical decisions such as licensing the first vaccine with an adjuvant designed to 
activate Toll-like receptors or approval of new generic versions of complex molecules such 
as low-molecular-weight heparins, which broadens access to important medicines8.
Funding for the laboratories is provided via a combination of funds from the US government 
and a fraction of the fees paid by industry to review the products, which is distributed via a 
system of intramural project grants. This stable funding allows scientists the freedom to 
develop highly innovative programs across disciplines and to undertake challenging 
scientific questions that inform the regulation of existing or developing products. Young 
immunologists will find that the FDA has one of the strongest professional development 
programs spanning myriad regulatory and basic science issues, and its scientists frequently 
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participate together with those of the NIH in such groups as the Immunology Interest Group, 
Glycobiology Interest Group, Cytokine Interest Group and Virology Interest Group that 
foster interactions and collaborations.
The practical effect of strong research programs at the FDA is clear, as they allow the FDA 
to keep up with rapidly evolving manufacturing and bioanalytical characterization 
technologies, understanding the mechanism of action of ground-breaking products, and 
foreseeing potential safety risks. In this manner, the FDA can face new challenges, whether 
they take the form of new therapeutics for emerging pathogens, novel delivery systems, 
‘biosimilars’ or intelligent devices, without excessive timidity, which would delay 
innovation. For example, immunologists at the FDA have focused on the factors that 
determine the immunogenicity of therapeutic proteins such as replacement enzymes and 
blood factors, for which immune responses to products can negate their effect or even result 
in the development of autoimmune disease in patients. Improved understanding of the 
factors involved in protein immunogenicity has led the industry to improve bioanalytical 
characterization and clinical monitoring, as well as to develop tolerizing regimens where 
indicated. Together this has resulted in improved therapeutic efficacy and product safety. It is 
thorough such understanding of basic science, current technology and patient needs, as well 
as the challenges of existing therapies, that has pushed scientists at the FDA to advocate the 
concept of ‘biobetters’—that, is the generation of new, improved versions of existing 
biological agents that would benefit patients by diminishing the adverse outcomes of many 
diseases and might reduce health care costs.
Thus, working for the FDA often provides scientists with a very tangible sense of having an 
effect on the development of new vaccines and therapies for unmet medical needs. As Cindy 
Buhse (Director, Office of Testing and Research) said,
“I worked for 15 years in industry with reduced back orders, stock holder value and 
sales figures as motivators, so for me, it is the FDA mission of Public Health that 
makes coming to work exciting”.
The CDC
The CDC is the health-protection agency of the USA. Its mission is to protect the USA from 
threats to health, safety and security, both domestic and foreign. Its role is to detect and 
respond to new and emerging health threats, such as severe acute respiratory syndrome, 
Middle East respiratory syndrome, the influenza virus H1N1 pandemic, anthrax, HIV-AIDS 
and Ebola virus, and to put science and technology into action to prevent disease, to develop 
and train public health leaders and to contribute to global health security. It is an exciting 
place to work for researchers interested in having a direct effect on public health.
The CDC’s main campus is located in Atlanta, Georgia, and the majority of its laboratories 
are located there. However, there are laboratories located at other CDC facilities around the 
country, including Fort Collins, Colorado; Puerto Rico; Alaska; and Cincinnati, Ohio. 
Although most of the CDC’s laboratories are focused on infectious diseases, there are also 
opportunities in environmental health and newborn-screening programs. The infectious 
diseases laboratories are housed in four centers, each with a different focus and mission: the 
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National Center for Immunization and Respiratory Diseases; the National Center for 
Emerging and Zoonotic Infectious Diseases; the National Center for HIV/AIDS, Viral 
Hepatitis, Sexually Transmitted Diseases and Tuberculosis Prevention; and the Center for 
Global Health. Laboratories in these centers are generally dedicated to specific organisms, 
and immunologists wishing to pursue a career at the bench will find an exciting range of 
opportunities in infectious disease immunology. These can range from cutting-edge 
pathogenesis studies to novel assay development and clinical trial support.
Fellowship opportunities for both those with a newly minted PhD and post-doctoral fellows 
are offered through discrete programs such as the American Society for Microbiology 
fellowship program and the usual hiring mechanisms (https://www.usajobs.gov). Once at 
CDC, it is impossible not to absorb the basic principles of public health epidemiology, 
which is the ‘bread and butter’ of the CDC. Laboratory diagnostics are essential for the 
investigation of outbreaks and disease surveillance in both global settings and domestic 
settings. Vaccine research is another area in which immunologists may find their niche, 
whether in the quest for a universal vaccine against influenza virus or evaluating a novel 
adjuvant or developing assays for monitoring the immune response to a novel vaccine in 
clinical trial. Local academic partners provide excellent opportunities for collaborations with 
cutting-edge basic research in immunology9. The laboratories of the CDC also collaborate 
with and provide support to state public health labs and to networks of laboratories around 
the world. Many of CDC’s laboratories serve as collaborating centers with the World Health 
Organization (http://www.pepfar.gov and http://www.who.int/collaboratingcentres/en/).
The Epidemic Intelligence Service is a highly-sought-after 2-year training program for those 
interested in combining their specific skills with formal training in epidemiology (https://
www.usajobs.gov and http://www.cdc.gov/eis/). These positions are part of the US Public 
Health Service Commissioned Corps, which is a uniformed service. Of note, everyone on 
the CDC staff, whether a member of that corps or not, has access to preparedness training at 
the CDC and may serve in the Emergency Operations Center when it is activated for 
responses to emergencies such as the 2010 earthquake in Haiti, the 2009 influenza virus 
H1N1 pandemic or the ongoing Ebola virus crisis in West Africa.
For those who want to forge a path away from the laboratory, there are opportunities in 
laboratory science management, which can include science policy, biosafety and biosecurity 
issues, and technology transfer. Laboratory science management is an essential function and 
becomes more visible at higher levels of the centers. With the many public health problems 
being tackled by the US government, there is never a dull day!
Concluding remarks
The governmental agencies described in this Commentary—the NIH, FDA and CDC— 
present to immunologists a wide spectrum of stable career paths. In these agencies, 
immunologists can apply their knowledge and expertise to help solve public health issues. 
Whether researchers pursue a bench-driven career or the ability to apply their skills in a 
broader area, the highly collaborative and multidisciplinary characteristic of these 
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institutions allow exploration inside and across agencies of other areas of work that will 
enrich the research experience and contribute to career development and growth.
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Figure. 
Many researchers seek careers in academia, the pharmaceutical and biotechnology industry 
and others. An attractive alternative is pursuing a scientific career in government institutions.
Catalfamo et al. Page 9
Nat Immunol. Author manuscript; available in PMC 2018 February 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
